康希诺生物：曼海欣®获得《药品补充申请批准通知书》

Core Viewpoint - The company has received approval from the National Medical Products Administration of China for an expanded age range for its meningococcal polysaccharide conjugate vaccine, MCV4, from children aged 3 months to 3 years to children aged 3 months to 6 years [1] Group 1 - The approval allows the company's product, MCV4 (marketed as Manhaixin®), to be administered to a broader age group, enhancing its market potential [1] - Manhaixin® is the first quadrivalent meningococcal conjugate vaccine in China, addressing the gap in high-end vaccines in the country and improving disease prevention for children under 6 years old [1] - The innovative advantages of Manhaixin® have led to a strong market performance, with a continuous increase in market share [1]